RATIFY: Primary endpoint: Overall survival
The RATIFY study demonstrated significant and sustained survival benefits in adult patients with newly diagnosed acute myeloid leukaemia (AML) with FLT3 mutation receiving midostaurin. 1 The overall survival of patients in the midostaurin...